858 Therapeutics Stock

Develops small molecule therapeutics targeting novel oncology and immunology pathways, with lead program ETX-19477 in Phase 1 trials for solid tumors.

Buy

Buy 858 Therapeutics shares

Sign up to view historical trading trends and place an offer.

Sell

Sell 858 Therapeutics shares

Understand share pricing, list anonymously, and benefit from transparent fees.

Overview

858 Therapeutics is a clinical-stage biotechnology company focused on developing small molecule therapeutics targeting novel oncology and immunology pathways. Its lead program, ETX-19477, is a potent and selective inhibitor of the DNA repair protein PARG, currently undergoing Phase 1 clinical trials for patients with advanced solid tumors. The company also has preclinical assets targeting ADAR1, METTL3, and QPCT/L, aiming to address unmet needs in cancer and immune diseases.

Sector

Healthcare & Life Sciences

Founded

2019

Headquarters

San Diego, CA

Buy

Buy 858 Therapeutics shares

Sign up to view historical trading trends and place an offer.

Sell

Sell 858 Therapeutics shares

Understand share pricing, list anonymously, and benefit from transparent fees.

858 Therapeutics Management Team

858 Therapeutics people and management

  • CEO
    Jeffrey Stafford
  • Chief Medical Officer
    Ron Weitzman
  • Chief Scientific Officer
    James Veal

858 Therapeutics Valuations & Financials

Gain Insights Into 858 Therapeutics Stock Valuation & Share Prices

View real-time NPM data on 858 Therapeutics stock including daily 858 Therapeutics stock price estimates, valuation history, and historical share price information. Access 858 Therapeutics financing rounds, secondary trade levels, cap table data, and private company comparable transactions. Use NPM's private company valuation database to track 858 Therapeutics pricing across six independent market signals. Looking for private company due diligence data sources on 858 Therapeutics? Get in touch to learn more.

Similar Companies

Explore companies

like 858 Therapeutics

  • Ziphius Vaccines

    Healthcare & Life Sciences

    Develops self-amplifying RNA technology for vaccines and gene therapies, using specialized nanoparticle delivery to treat diseases and disorders.

  • DeepScribe

    Healthcare & Life Sciences

    Transforms clinician-patient conversations into complete, autonomous SOAP notes to streamline documentation and enhance patient care.

  • IntelyCare

    Healthcare & Life Sciences

    Operates a digital workforce platform to optimize nursing schedules and fill per-diem shifts at clinical facilities.

  • Exer Labs

    Healthcare & Life Sciences

    Delivers AI-powered motion analysis for real-time feedback and insights in fitness, health, and physical therapy.

  • NuEyes Technologies

    Healthcare & Life Sciences

    Engineers augmented reality smart glasses to enhance visual capabilities for low-vision patients.

  • Affinia Therapeutics

    Healthcare & Life Sciences

    Develops next-generation gene therapies by designing novel AAV capsids to improve targeting, safety, and efficacy for serious diseases.

  • Proniras

    Healthcare & Life Sciences

    Develops novel small-molecule therapeutics for substance use and specialty CNS disorders targeting unmet medical needs.

  • CivicEye

    Healthcare & Life Sciences

    Delivers advanced cloud-based software that streamlines operations for law enforcement and public safety professionals.

  • Newomics

    Healthcare & Life Sciences

    Delivers microfluidic chips and multinozzle ionization platforms that enhance sample sensitivity and throughput for mass spectrometry workflows.

FAQ

Questions?

We have answers

Buy 858 Therapeutics Stock

858 Therapeutics stock does not trade on public stock exchanges. 858 Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in 858 Therapeutics stock you can either buy shares directly through the company or work with a secondary trading marketplace like Nasdaq Private Market.

Learn more about the secondary market for private company shares on the investors page.

Sell 858 Therapeutics Stock

858 Therapeutics Stock does not trade on public stock exchanges. In order to sell 858 Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.

Learn more about NPM services for selling privately held stock on the Employee Shareholders page.

Read more about how to sell private company stock on the private secondary market:

 

858 Therapeutics Stock Price

858 Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the NPM Data and Intelligence database from Nasdaq Private Market, you can view 858 Therapeutics share price and other valuable private market data.

Read more about secondary market private company stock prices:

858 Therapeutics Stock Ticker Symbol

There is no ticker symbol for 858 Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.

Criteria to Sell 858 Therapeutics Stock

Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell 858 Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.

Learn more about selling privately held stock on the Employee Shareholders page.

Read more about how to sell shares of a private company and eligibility for selling privately held stock:

 

Criteria to Buy or Invest in 858 Therapeutics Stock

Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in 858 Therapeutics stock, you need to be an accredited entity or institutional investor.

Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.

858 Therapeutics Stock Settlement

Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.

To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.

858 Therapeutics IPO

858 Therapeutics is a private company and has not had an IPO. There is currently no 858 Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Data and Intelligence database and gain access to actionable data related to 858 Therapeutics IPO.

Learn more about Data and Intelligence private company stock data for institutional investors on the on the NPM Data and Intelligence Product Page.